期刊文献+

西格列汀联合胰岛素治疗脆性糖尿病患者的临床疗效分析 被引量:1

下载PDF
导出
摘要 目的观察西格列汀联合胰岛素治疗脆性糖尿病的临床疗效。方法 90例脆性糖尿病患者作为研究对象,随机分为研究组和对照组,每组45例。对照组患者单纯采用胰岛素治疗,研究组患者采用西格列汀联合胰岛素治疗。观察比较两组患者治疗后血糖控制情况(空腹血糖、餐后2 h血糖)及日内血糖变异情况[全天血糖标准差(SD)、最大血糖波动幅度(LAGE)、餐后血糖波动幅度(PPGE)]。结果治疗后,研究组患者空腹血糖(5.66±0.63)mmol/L及餐后2 h血糖(7.24±0.33)mmol/L均明显低于对照组的(9.22±1.98)、(12.13±2.88)mmol/L,差异均有统计学意义(P<0.05)。治疗后,研究组患者SD(0.91±0.24)mmol/L、LAGE(3.35±0.56)mmol/L及PPGE(1.62±0.51)mmol/L均明显低于对照组的(1.88±0.62)、(7.35±0.80)、(2.59±0.47)mmol/L,差异均有统计学意义(P<0.05)。结论西格列汀联合胰岛素治疗脆性糖尿病的临床效果显著,能够明显降低患者的血糖,有利于维持血糖水平稳定,且安全性高,值得临床推广。
作者 孟康
出处 《中国实用医药》 2019年第25期107-108,共2页 China Practical Medicine
  • 相关文献

参考文献10

二级参考文献68

  • 1Herman GA,Bergman A,Stevens C,et al. Effectsin of single oral doses of sitagliptin, a dipeptidyl peptidase-4inhibitor, on incretin and plasma glucose levels after an oral glucose toler ance test in patients with type 2 diabetes[J]. Clin Endocrinol Metab,2006,91(ll) :4 612-4 619.
  • 2Herman GA,Bergman A,Stevens C, et al. Effect of single oraldoses of sitagliptin, a dipeptidyl peptidase- 4 inhibitor, on incretin and plasma goucose levels following an oral glucose tolerance test in patients with type 2 diabets[J]. J C[[n Endocrinol Metah, 2006, 91:4612-4 619.
  • 3KimD, WangL, BeeoniM. et al. (2R)-4 o xo-4-[3 (trifluoromethyl) - 5,6 - dihydro [ 1,2,4 ]triazolo [ 4,3- a ]pyrazin- 7 (8 H) -yl] - ( 2,4,5 -t rifluorophenyl) butan - 2 - amine: a potent, orally acive dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes[J]. J Med Chem,2005, 48,141-151.
  • 4Drucker DJ, Nauck MA. GLP1R agonists (incretin mimetics)and DPP-4 inhibitors (ineretin enhancers) for the treatment of tupe 2 diabetds[J]. Lancet, 2006,368 : 141 - 151.
  • 5Vilsboll T, Hoist JJ. Incretins, insulin secretion and type diabe tes[J]. Diabetologia, 2004,47 : 357-366.
  • 6Wang Q, Li L,Xu E,et al. Glucagon-like peptide-I regulates proliferation and apoptosis visa activation protein kinase B in pancreatic INS- 1 beta cells [J]. Diabetologia, 2004, 47: 478-487.
  • 7Stoffers DA. The development of beta-cell mass: recent progress and peoliferation role of GLP- 1 [J]. Horm Res, 2004, 36:811-821.
  • 8Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes[J]. Curr MedResOpin,2008,24(2):537-550.
  • 9Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes[J]. Diabetes Res Clin Praet,2008,79(2):291-298.
  • 10Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin[J]. Diabetes Obes Metab,2007,9(5) :733-745.

共引文献60

同被引文献17

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部